<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2013</study_start_year><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2171644</full_dataset_link><location>Spain</location><study_start_month>3</study_start_month><repository>ECRIN MDR</repository><study_status>Terminated</study_status></additional><is_claimable>false</is_claimable><name>Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment</name><description>The purpose of this study is to determine efficacy and safety of cabazitaxel administration in patients with colorectal cancer resistant to standard treatment.</description><dates><creation>2013-03-15</creation></dates><accession>2171644</accession><cross_references><ClinicalTrials___gov>NCT02204332</ClinicalTrials___gov></cross_references></HashMap>